SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank the patients who took part in the study and their families, as well as the staff, research coordinators, and investigators at each participating institution. We gratefully acknowledge the support of the CoCo Neurosciences study group and the LOC network.

Ethical approval

The study was conducted in compliance with the Declaration of Helsinki. Approval was obtained from the local ethics committee (IRB approval 2020CER-202028).

Author contributions

AL, CH and KHX designed the study. AL, CH, RU, ET, VH, GA, SC, CS, CMC, BM, KM, VP, LN, SM and MT collected the data. AL and CH reviewed and analyzed the clinical data. AL and CH wrote the initial draft, with input from all authors. All authors participated in data analysis, reviewed and approved the final manuscript.

Disclosure statement

All authors report no disclosures relevant to the manuscript. MT has a consulting or advisory role with Agios Pharmaceutical, Integragen, and Taiho Oncology, and research funding from Sanofi.

Additional information

Funding

This work was in part supported by a grant INCa-DGOS-Inserm_12560 of the SiRIC CURAMUS, Institut National du Cancer (INCa). The Cohort COVID-19 Neurosciences (CoCo Neurosciences) study was sponsored by APHP and funded by the generous support of the FIA (Fédération Internationale pour l’Automobile) Foundation and donors of the Paris Brain Institute – ICM. The research leading to these results has received funding from the program “Investissements d’avenir” ANR-10- IAIHU-06.